The federal government negotiated with drug makers to bring lower prices on GLP-1 drugs to millions of Medicare patients.

The agency is able to negotiate some drug prices for Medicare recipients because of a bill signed by former President Joe ...

The White House recently announced a landmark deal with pharmaceutical companies Eli Lilly and Nordisk that will impact Medicare beneficiaries and others in the coming months. The agreement cuts ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

The Trump administration says it will not move forward with a Biden proposal that Medicare cover anti-obesity drugs such as Novo Nordisk’s Wegovy and Zepbound from Eli Lilly. The drugs have been shown ...

ACCESS is a decade-long initiative to expand tech-enabled care and outcome-based payments for Medicare patients with obesity, ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Thirteen states cover GLP-1 drugs through their Medicaid programs, and others are considering following suit (Mario Tama/Getty Images). President Donald Trump and Health Secretary Robert F. Kennedy Jr ...

WASHINGTON -- The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move.

President Trump has successfully negotiated a groundbreaking deal to include obesity drugs under Medicare coverage, marking a significant shift in healthcare policy. This agreement, announced on ...